ProfoundBio discovers the joys of having a wealthy owner
The company has become the latest in a recent string of China-related innovative drug makers to be purchased by larger foreign buyers Key Takeaways: Cancer treatment maker ProfoundBio announced it…
AstraZeneca pays hefty price for Chinese weight-loss drug
The drugs giant has licensed an experimental anti-obesity pill from China’s Eccogene as it tries to grab a chunk of the lucrative weight-loss market Key Takeaways: Chinese biotech Eccogene says…
Drug maker Junshi seeks Swiss cure for cash woes
The biotech aims to raise 3.4 billion yuan through Swiss GDRs in its second major fund-raising push in just over six months Key Takeaways: Junshi Biosciences reported dismal results in…
Missing the Covid boat, Junshi stumbles back to old business
Despite developing an oral drug to treat Covid, the biotech company's revenue fell sharply and its net loss widened by nearly 40% in the first quarter Key Takeaways: Junshi Bioscience's…
ImmuneOnco banks on cutting-edge cancer drugs to attract IPO cash
The biopharma wants to use IPO proceeds to bring its cancer immunotherapies to market, having already built a lofty valuation with backers such as Eli Lilly Key Takeaways: ImmuneOnco’s main…
Henlius Swallows Bitter Pill in Watered-Down Licensing Deal
The innovative drug company will receive less benefits from an existing licensing deal after revisions to reflect high R&D costs Key Takeaways: Henlius Biotech will receive up to $11 million…
New Drugs Approvals Bring No Relief for Ailing Innovent Bio
The innovative drug maker has been approved to sell two more cancer drugs in China, but that hasn’t lifted its stock price Key Takeaways: Innovent Bio has brought several drugs…
Recent Articles
Drug maker Junshi seeks Swiss cure for cash woes
1877.HK
688150.SHG
Missing the Covid boat, Junshi stumbles back to old business
1877.HK
688180.SHG
RELATED ARTICLES
-
AstraZeneca pays hefty price for Chinese weight-loss drug
AZN.US
-
BeiGene goes for global growth with sales and R&D push
BGNE.US 6160.HK
-
CStone breaks up with drugs partner as U.S. rollout stalls
2616.HK
- InSilico seeks IPO boost to get AI drugs over the line
-
Everest reaches new heights on growing drug sales
1952.HK
-
Profit setback for Simcere Pharma in novel drugs quest
2096.HK
-
Drug maker Junshi seeks Swiss cure for cash woes
1877.HK 688150.SHG
